Abstract
Increased utilisation of active surveillance (AS) enhances the cost effectiveness of prostate cancer screening, with screening becoming cost effective at high AS uptake rates.
With current Australian treatment patterns, prostate cancer screening is more cost effective than the current Australian breast cancer screening programme.
Introduction
Prostate cancer (PC) is currently the most commonly diagnosed cancer in Australia, after non-melanomatous skin cancer, with Australia and New Zealand having amongst the highest incidences in the world [1, 2] .
PC deaths in Australia totalled 3294 in 2011, the last year for which data is available, making it the fourth most common cause of death in Australian males, and the second most common cause of cancer-related death after lung cancer [3] . PC mortality consequently outnumbers both breast (2680) and sex-specific bowel cancer deaths (2219 deaths in men), both of which have established populationbased screening programmes [3] .
Despite the documented burden of disease that PC presents, the Royal Australian College of General Practitioners' (RACGP) guidelines currently recommend against discussing the subject of PC screening unless the subject is raised by the patients themselves [4] .
The RACGP cite the recent prostate-specific antigen (PSA)-based population screening studies of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) and the 2009 results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) as evidence of no mortality benefit for PSA-based PC screening [4] . However, both PLCO and ERSPC studies suffered from methodological failures [5] . The PLCO had a short screening period of only 6 years, a high proportion of randomised patients (44 %) having had a serum PSA performed in the last 3 years, and 52 % of the control group receiving a PSA test over the 6-year screening period [6] . Compared with the Göteborg trial, the ERSPC had heterogeneous, and on average higher, PSA thresholds (2.5-10 ng/mL) and heterogeneous, and on average longer, screening intervals (2-7 years) and shorter followup [7, 8] .
The more recently published results of the Göteborg randomised population-based PC screening trial have demonstrated the greatest survival benefit and lowest number needed to treat (NNT) of any of the PSA screening trials [8] . Of the randomised controlled trials exploring PSA-based population screening, the Göteborg trial has the longest follow-up and the most robust trial protocol with a standardised serum PSA threshold (2.5 ng/mL) and a test interval of 2 years for the duration of the trial [8] .
The cost effectiveness of PC screening has also been explored in numerous cost-effectiveness analyses (CEAs) which have produced widely varying results. No CEA to date, however, has used the findings of the Göteborg cohort, with most modelling the results of the 9-year follow-up data from the ERSPC, which had a significantly higher NNT [9] [10] [11] .
Active surveillance (AS), an approach of monitoring rather than immediately treating low-risk PC, has been demonstrated to decrease the harm of overtreatment, whilst preserving the benefits of screening [12] . Decision analyses investigating the cost effectiveness of AS protocols compared with primary intervention for low-risk PC found that AS dominated primary intervention at all modelled time horizons [13, 14] .
Aim
We aimed to investigate the predicted cost utility of a theoretical Australian PSA-based population screening programme. In our model, PC diagnoses were risk stratified, and any subsequent treatment based upon current Australian treatment patterns. The accumulated costs, utilities and cancer-specific mortality rates between hypothetical screening and non-screening cohorts were recorded and compared. We aimed to compare two systematic screening strategies with current opportunistic screening practices: (1) a screening strategy where any cancer diagnoses would be treated in accordance with current Australian treatment patterns and (2) an AS-optimised strategy where any low-risk PC diagnoses were followed with an AS protocol instead of receiving primary intervention until clinical disease progression.
Methodology

Study Population
The model evaluated the outcomes of a uniformly distributed Australian male cohort aged between 50 and 69 years. A uniform distribution was selected to better reflect the recruitment method of the Göteborg study, as opposed to all men entering the model at a set age, as is commonly employed in other decision models [9] [10] [11] .
Screening Strategies
The model assessed the cost utility of two screening strategies for PC: Strategy 1-a systematic population screening strategy, with invitation for screening with a serum PSA test every 2 years, with any supra-threshold PSA tests offered a trans-rectal ultrasound-guided biopsy (TRUS); Strategy 2-opportunistic PC screening, representing current standard practice.
Two separate scenarios were created utilising the same two screening strategies. The first scenario, or base case, compared both screening programmes with any subsequent PC diagnoses being treated in accordance with current Australian clinical practices, with treatment strategies determined by both cancer risk stratification and patient preference. The second scenario, or the AS-optimised model, differed in that subsequent low-risk PC diagnoses were all treated initially with AS instead of the majority of cases receiving primary intervention. Those on AS that had PSA progression (PSA C10 ng/mL) or PC upgrading (Gleason score [6) on subsequent TRUS biopsy would proceed to definitive intervention based upon their new risk stratification.
Markov Model Structure and Health States
To investigate the cost utility of a PSA-based screening programme in a simulated Australian population we built a decision model utilising Markov processes in TreeAge Pro 2014 software suite (TreeAge Software Inc., Williamstown, MA, USA).
All men entered the model in a cancer-free/pre-diagnosis health state. Literature-based probabilities saw men either (1) remain disease free, (2) die of background (non-PC) causes, or diagnosed with (3) low-risk, (4) intermediate-risk, (5) high-risk or (6) advanced (metastatic) PC.
Following diagnosis of non-metastatic PC, the patient would either undergo AS (surveillance with curative intent, limited to those with low-risk diagnoses), surgery, radiation or watchful waiting (WW; surveillance with palliative intent, limited to those with a life expectancy of \10 years or contraindications to curative therapy). Curative treatment options were limited to the most commonly available Australian treatment options of radical retro-pubic prostatectomy (RRP) and external beam radiation therapy (EBRT). Following diagnosis and treatment, men would stay in risk-stratified post-treatment health states until natural death or development of metastatic disease (Fig. 1) .
In line with the Göteborg study, PSA screening would cease once a patient reached the age of 69 years, but they would continue to cycle through the model [8] . A 1-year cycle length was selected to best represent the slow natural history of PC. A 20-year time horizon was selected owing to the paucity of quality literature on both the natural history of PC and EBRT failure rates after this length of time.
Model Inputs
Electronic literature searches utilising PubMed, Ovid MEDLINE and The Cochrane Library were performed to select model inputs for transition probabilities, utilities and costs. Australian studies were preferentially selected when available and where follow-up was appropriate for the model timeline. Where Australian studies were unable to wholly cover the timeline of the model, they were synthesised with estimates from international literature with longer follow-up. Where Australian studies were wholly lacking, mostly in the case of transition probabilities, hand selection of the international literature was performed. Synthesised estimates were given preference over estimates from individual series. Where systematic reviews were nonexistent, individual papers were analysed, with those papers with protocols best representing current Australian practice, the largest numbers of recruited patients and the longest follow-up, where appropriate, being selected.
Probabilities
Probabilities of diagnoses of low-, intermediate-, high-risk and advanced disease were drawn from the cumulative incidences for each diagnosis in both screening and control populations in the Göteborg study [8] [15] .
Current treatment practices for each PC risk classification were drawn from Australian data [16, 17] . Treatments were limited to RRP, EBRT, WW and AS as these are the most universally available Australian treatment options. AS was only an option for patients diagnosed with low-risk disease, consistent with current European Association of Urology guidelines and similar to those of the Prostate Cancer Foundation of Australia, which allows very low volume Gleason 3?4 and PSA values of \20 ng/mL [18, 19] (Table 1 ). In the base case (Scenario 1), the AS uptake rate was as per current Australian treatment patterns (15 % of low-risk diagnoses); in Scenario 2, all low-risk diagnoses were treated with AS until clinical disease progression (serum PSA C10 or Gleason score [6 on subsequent biopsy).
Probability of progression to definitive therapy after entering the AS disease state was derived from a synthesisbased estimate of AS series, and was dependant on time spent in the disease state [20] . Progression rates in the short term (5 years) were similar to rates from an Australian AS cohort [17] .
A treatment threshold of C76 years old was selected as described in Campbell-Walsh Urology. At this age all patients currently in the AS health state would transition to the WW health state [21] .
Probabilities of disease recurrence for each risk stratification following definitive treatment were derived from analysis of 6652 D'Amico risk-stratified men receiving PC therapy at a high-volume centre [22] .
Probability of disease progression to metastasis for those in WW disease states was drawn from the Prostate Intervention Versus Observation Trial (PIVOT), being more contemporaneous (published 2012 vs. 2002), with longer median follow-up (10 vs. 6.2 years) and having more participants in the observation arm (367 vs. 349 men) than the next largest study published by Holmberg et al. [23, 24] .
Risk of progression to the advanced disease state following post-treatment recurrence was drawn from an international study which followed 2426 men with biochemical recurrence after RRP with a median follow-up of 6.6 years [25] .
Adjustment for the possibility of initial clinical understaging of low-risk disease was performed, utilising the results of the largest published prostatectomy specimen series of 626 patients meeting the strict Prostate Cancer Research International: Active Surveillance (PRIAS) criteria [26] .
Probabilities of background mortality were drawn from Australian Bureau of Statistics age-related mortality rates, and adjustments made for age-related PC-specific death rates [27, 28] . Although there is evidence that androgen deprivation therapy (ADT) might increase the rate of cardiovascular events, an increase in cardiovascular mortality has not been conclusively demonstrated, with significant discordance in results between published trials [29] [30] [31] . Additionally, in our model, ADT was only initiated when metastases were present, reflecting more conservative practice and resulting in lower total ADT exposure. As such, we did not adjust the transition probability to noncancer-related death for those in the metastatic disease state. We also did not adjust for peri-operative mortality in the RRP group; however, the paper by Björklund et al. demonstrated that the 90-day peri-operative mortality in [22,000 men receiving RRP was lower than the agematched cohort (\0.2 %) [32] .
Utility Values
Health states were each assigned a utility value representing the health-related quality of life of an average patient (Table 2) .
PC screening has been criticised as increasing anxiety and reducing health-related quality of life (HRQoL) during and after diagnosis [4] . However, in the Dutch and Finnish centres of the ERSPC it was shown that screening does not induce short-term HRQoL effect [33, 34] . Even those patients who had false positive results tended to regard screening as a positive experience [35] . Likewise, participating in an AS protocol does not appear to impact HRQoL or increase anxiety when compared with controls, with Proceed to RRP 0.534 0.020967921 [60] Proceed to WW # Diagnosed high-risk PC Proceed to EBRT 0.4513333333 0.0374038546 [60] Proceed to RRP 0.452 0.0374087213 [60] Proceed to WW # AS \76 years Develop advanced disease whilst on AS 0.00523 0.000425 [14] Proceed to definitive treatment first 5 years 0.0643706623 0.0077606108 [20] Proceed to definitive treatment second 5 years 0.0323158832 0.0055920986 [20] Proceed to definitive treatment third 5 years 0.0188410491 0.0042995423 [20] AS C76 years Proceed to WW 1 N/A [21] AS to definitive therapy Proceed to EBRT 0.2962962963 0.0367957508 [17] Proceed to RRP 0.6296296296 0.0389135037 [17] Proceed to WW # participants' HRQoL similar to age-adjusted controls [34, 36, 37] . Utility scores were consequently unaffected by screening or AS in our model. We elected to use a single Australian study for our posttreatment utility scores. Smith et al. followed the same large cohort (1500) of 50-to 69-year-old men for 3 years before and after definitive treatment, comparing their utility directly against an age-and pre-morbidity-matched control cohort over the same 3-year period, using the same health instrument. This study utilised the University of California PC index, a validated instrument which includes all 12 components of the commonly used 12-item short form (SF-12) questionnaire. They demonstrated a relative utility value of 0.95 when compared with age-matched controls at 3 years following treatment [36] .
Despite widely ranging protocols for administration of androgen deprivation therapy, our model conservatively initiated its usage only when patients transitioned to the metastatic health state. Of the treatment options, androgen deprivation therapy is widely regarding as having the greatest effect on HRQoL, however, this may reflect the poor baseline of patients selected for androgen deprivation therapy [36, 38] . The metastatic health state utility value was drawn from a combination of Australian and international studies [36, 39] . The Australian HRQoL study by Smith et al. demonstrated a utility of 0.9 at initiation of androgen deprivation therapy; however, follow-up was inadequate to assess the utility of terminal PC [36] . The utility of PC at its terminal stage was drawn from the study by Färkkilä et al., which assessed HRQoL using multiple health instruments (15D, EQ-5D, VAS, EORTC QLQ-C30) and from which our utility value of terminal PC of 0.6 was synthesised [39] . The utility of the advanced disease state thus fell from 0.9 to 0.6 over a 5-year period to represent deteriorating wellbeing with increasing burden of disease. This terminal illness health state utility is quite conservative compared with other Cost-Utility analyses [10, 38] .
All utility values for disease states listed above were not absolute values, but were multipliers for the age-related baseline utility in a contemporary Australian male population [40] .
Costs
Costs were accumulated by both being in a specific disease state (state costs) as well discrete events (transition costs), such as having surgery.
A health system perspective was used to assign costs for screening, AS and treatment, as the model aims to approximate the costs of a government-run screening programme. Out-of-pocket and time costs for programme participants were therefore not included. Transition and state costings were derived from a combination of Australian studies, Medicare Benefits Schedule (MBS), Pharmaceutical Benefits Scheme (PBS) and Australian RefinedDiagnosis Related Groups (AR-DRGs) ( Table 3 ). All costs were inflated to 10 July 2015 Australian dollars (A$) using annual inflation rates from the Reserve Bank of Australia.
The cost of annual screening was calculated from the overall number of PSA blood tests and TRUS biopsies performed in the Göteborg study. A fractional annual test frequency per patient was calculated after adjusting for model dropout for either natural death or reaching the age limit of screening. The Australian costs of a serum PSA test and a TRUS biopsy, allowing for a 2 % rate of post-TRUS sepsis, were then used to arrive at the final cost of screening per man aged 50-69 years in the screening cohort [21] .
Model Outcomes
The primary model output was quality-adjusted life-years (QALYs) for each screening strategy over 20 years. Cost effectiveness was measured as an incremental cost-effectiveness ratio (ICER) and expressed in $/QALY. Life-years gained (LYG) was used as an alternative model output to allow comparison with other cost analyses that did not use the QALY metric.
All future costs, QALYs and LYGs were discounted 5 % and compared with a societal willingness to pay (WTP) of A$50,000/QALY in line with Pharmaceutical Benefits Advisory Committee guidelines and a half-cycle correction was applied to all Markov processes [41] . Undiscounted QALYs and LYGs are also presented due to ongoing controversy regarding the discounting of future health outcomes, particularly for screening and prevention programmes [42, 43] . Cancer-specific mortalities and interventions saved per 10,000 men were also used to compare treatment strategies.
Univariate Sensitivity Analysis
We conducted univariate sensitivity analyses of all probabilities, cost and utility values to determine the effect of uncertainty of each variable upon the model's Advanced disease a 0.9 to [0.6 over 5 years [36, 39] a Values are not absolute, but multipliers of the age-dependant baseline utility value output. All cost and utility values were varied 20 % above and below the base-case value. Transition probabilities were varied within their 95 % confidence intervals. Simulations were also run with a lifelong timeline and a cohort start age of 50 years to assess possible impact on model outcomes. Univariate sensitivity analysis outside of the confidence intervals was performed for the probability of entering the AS health state following a diagnosis of low-risk PC. This was done to determine what rate of primary AS was required in order to achieve an increase in QALYs at a subthreshold WTP value.
Probabilistic Sensitivity Analysis
Multivariate probabilistic sensitivity analysis was performed for all variables in both scenarios to assess overall model uncertainty. A second-order Monte Carlo analysis was performed with all variables drawn simultaneously. Beta and gamma distributions were estimated for utility and costing values, respectively, from normal distributions with standard deviations of 20 % above and below the base-case values. A combination of Dirichlet and beta distributions were drawn for probability values based on their standard error values, as per Table 1 . A total of AR-DRGs Australian Refined-Diagnosis Related Groups, AS active surveillance, CT computerised tomography, DPMQ dispensed price for maximum quantity, EBRT external beam radiation therapy, MBS Medicare Benefits Schedule, PBS Pharmaceutical Benefits Scheme, PSA prostate-specific antigen, RRP retro-pubic radical prostatectomy, Rx treatment, TRUS trans-rectal ultrasound guided prostate biopsy, WW watchful waiting 10,000 samples were drawn for each probabilistic sensitivity analysis.
External Validation
In order to validate our models, we ran our base-case model with a 15-year time horizon and 9958 men in each arm, to simulate the follow-up and cohort numbers of the Göteborg study. Our model very closely replicated the number of deaths from both PC and background mortality in the Göteborg study with 40 screening and 72 nonscreening PC-specific deaths, and 1791 screening and 1788 non-screening deaths from background mortality. This compares with 44 screening and 78 non-screening PCspecific deaths, and 1937 screening and 1904 non-screening deaths from background mortality in the Göteborg study.
Results
Scenario 1-Base Case
With conservative modelling, our theoretical population screening programme base case yielded an additional 0. 
Scenario 2-Optimised Active Surveillance
In our AS-optimised scenario, the screening programme generated higher incremental QALYs than Scenario 1 (base case), with an additional 0.01222 QALYs per patient when compared with the opportunistic screening group. The cost of screening was also lower than in Scenario 1, with an additional cost of A$560 per patient in the opportunistic screening group. This yielded an ICER for the AS-optimised screening scenario of A$45,882/QALY compared with opportunistic screening (Table 4) .
With QALYs undiscounted, an additional 0.0229 QALYS per patient were gained with the screening programme, yielding an ICER of A$24,483/QALY. Whilst the AS-optimised screening Scenario 2 dominated Scenario 1 (base case) in which usual treatment approaches were implemented, this increase in QALYs and reduction in cost compared with Scenario 1 came at the expense of one additional PC-specific death per 10,000 men in both screened and unscreened cohorts. The number of interventions performed in both the screening (208 fewer RRP, 355 fewer EBRT) and non-screening groups (105 fewer RRP, 149 fewer EBRT) per 10,000 men was significantly reduced.
Univariate Sensitivity Analyses
Univariate sensitivity analyses of both modelled scenarios were dominated by utility following definitive therapy, particularly for Model 1. Varying the post-definitive therapy utility co-efficient from 0.95 to 0.90 led to net disutility for the entire screening cohort in Model 1, and resulted in the point estimate for Model 2 exceeding the WTP threshold (Table 5) .
After post-treatment utility the next most influential variables were, in order: age-related utility, discount rate and the utility of advanced disease. Cost variability within 20 % of the base-case value had little effect on overall model output with almost all transition probabilities being more influential. Reducing the age of model entry to 50 years old, rather than utilising a uniform distribution between ages 50 and 69 years, had the effect of reducing the value of the point estimates without affecting the outcomes of the modelled scenarios. Similarly, utilising a lifelong timeline, as opposed to a 20-year time horizon resulted in lower point estimates without affecting scenario outcome. Whilst varying model inputs universally affected the value of the point estimates, it rarely affected the outcome; Scenario 1 remained cost ineffective and Scenario 2 remained cost effective in most simulations. Results of the four variables with the most influence on ICER in the univariate sensitivity analysis are presented in Tornado diagrams (Figs. 2, 3 ) and the ICERs of the most influential variables are presented in Table 4 .
When we varied the probability of entering the AS health state after a diagnosis of low-risk PC outside of its confidence intervals in Model 1, the screening arm became cost effective at an AS uptake rate of 91.9 % assuming an acceptable threshold for cost effectiveness of A$50,000/ QALY (Fig. 4) .
Probabilistic Sensitivity Analyses
Probabilistic sensitivity analysis was performed for base model (Scenario 1) in order to ascertain the proportion of simulations in which it proved cost effective. Assuming a WTP threshold of A$50,000/QALY, the base-case model was cost effective in 38 % of simulations, delivered improved QALYs at supra-threshold WTP in 38 %, and decreased QALYs in 24.5 % of simulations (Fig. 5) .
For Scenario 2, optimised AS, the probabilistic sensitivity analysis demonstrated cost effectiveness in 53 % of all simulations, provided an increase in QALYs at a suprathreshold WTP in 27 % of simulations and decreased QALYs in 19 % of simulations (Fig. 6) .
A cost-effectiveness acceptability curve was plotted for Scenario 2 to demonstrate the effect of increasing WTP on the number of cost-effective iterations; at a WTP of A$100,000/QALY, screening was cost effective in 66 % of all iterations (Fig. 7) .
Discussion
Our model is the first to explore the effectiveness and the cost of instituting a PSA-based population screening programme based on the results of the Göteborg randomised, population-based, PC-screening trial. Other CEAs to date ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year have based their assumptions upon the results of the PLCO or ERSPC trials; however, the protocols of both trials were flawed [5] .
In our base-case scenario, screening was not found to be cost effective as, although it increased QALYs, it did so at an incremental cost of A$147,528/QALY, which was well above our nominal WTP of A$50,000/QALY.
When the results are viewed with an LYG metric, the results appear more favourable with a cost of A$45,890/ LYG. It must be stressed that the seemingly large difference between the cost/QALY and cost/LYG is not due simply to patient disutility following treatment. Rather, as evidenced by the univariate sensitivity analysis, two of the most influential model variables were the pre-morbid utility score and the discount rate of future outcomes/costs; consequently, multiple lives needed to be extended in order to generate a single additional QALY. The cost effectiveness of our model compares favourably with other CEAs that have demonstrated highly variable results [9] .
Pataky et al. in a 2014 Canadian ERSPC-based micro-simulation study, found screening strategies cost between CAD $27,000 and CAD $54,000/LYG compared with non-screening strategies [9] . They also found that all strategies resulted in decreased QALYs for the screened population; however, this result was very sensitive to the utility values used [9] .
A 2011 American CEA based upon the NNT of the ERSPC (48 men) found at 9 years' follow-up that screening was not cost effective based upon their societal WTP of US $100,000/LYG [11] . However, they found that screening became cost effective when the NNT was \21, which compares favourably with the Göteborg study's NNT of 12 [8, 11] .
Only one CEA is published that aims to model an Australian PC screening programme, and it is based upon the 9-year follow-up data from the ERSPC [10] . This model failed to demonstrate cost utility for a population screening model in Australia, with a cost of A$291,817/QALY at 10 years' follow-up; however, this analysis disregards the role of AS completely [10] . Furthermore, every man in this model diagnosed with PC assumed a 0.05 disutility and all lifetime treatment costs immediately. This model also arguably overestimates costs by assuming the cost accrual of 100 % screening compliance while assuming the complianceunadjusted mortality reduction of the ERSPC, which had only 82 % of screened men having at least one PSA test, and 86 % of men undergoing TRUS when recommended [7] .
Whilst our model suggests population-based screening at current AS uptake rates is not cost effective when compared with Australia's WTP, it does appear to compare favourably with established Australian screening programmes. BreastScreen Australia have not performed a comprehensive Cost-Utility analysis to directly compare cost/QALY [44] . They have, however, performed a CEA, with the Markov model output unit being cost per LYG. Similar to our model, BreastScreen Australia also focused on a population of 50-to 69-year-olds, used a biennial screening test and a 5 % discount rate for future costs and benefits. After adjusting for inflation, the estimated cost per LYG over a 20-year time horizon was A$47,776/LYG [44] . Using the same LYG metric, a 5 % discount rate at a 20-year time horizon, PSA-based screening was more cost effective at A$45,890/LYG. Similarly, no true Cost-Utility analyses of the established Australian colon cancer screening programme have been performed; however, a CEA examining cost/LYG has been undertaken [45] . The projected cost, after adjustment to July 2015 dollars, of A$53,989/LYG was higher than for our PC model; however, the time horizon the authors in this study selected was only 10 years [46] .
A long-standing criticism of PC screening is the overdiagnosis and consequent overtreatment of clinically indolent cancers [7] . The increasing uptake of AS internationally might facilitate separation between low-grade PC diagnosis and its treatment [47, 48] . There is an increasing body of evidence demonstrating that AS can decrease the harm of overtreatment whilst maintaining the mortality benefits of screening [12, 49] . Indeed, while the base case for our model was found not to be cost effective based upon current Australian treatment preferences, the cost/QALY was shown to decrease dramatically with increased AS utilisation. Other CEAs investigating the role of AS in primary PC treatment have demonstrated that AS both increased QALYs and decreased treatment costs when compared with primary intervention [13, 14] . Koerber et al. found that AS dominated primary intervention for low-risk PC, with AS yielding both lower costs and higher QALYs across modelled time horizons of 5, 15 and 30 years' follow-up [14] . Orlendorf et al. found that while AS yielded higher lifetime treatment costs than primary intervention, this was offset by increased QALYs, with AS being the more cost-effective treatment [20] . Our study extends these promising findings to suggest the AS-optimised model may be cost effective in the Australian setting.
The AS uptake rate required for cost effectiveness in our model was 92 %, which while high, may not be unattainable. Data from the Victorian Prostate Cancer Registry (VPCR) demonstrates increasing AS utilisation in recent years, with 36 % of all new low-risk diagnoses initially selecting AS [50] . In Sweden, AS is now the most commonly selected primary treatment for low-risk PC, with 72 % of all new diagnoses initially managed with AS [51] .
Concerns about clinical under-grading and under-staging of PC exist and are perhaps contributing to underutilisation of AS as a treatment option for low-risk PC [26, 52] . However, the clinical effect of an initial undergrading of PC in AS patients is yet to be established and it is not reason enough to deny patients the option of AS. The un-marrying of PC diagnosis and its immediate treatment and the increased utilisation of AS as a treatment option are crucial to the cost effectiveness of PSA-based PC screening and essential in reducing screening-related harm [53, 54] .
This difficulty in establishing a disconnection between PC diagnosis and treatment might be alleviated by the increasing utilisation of multi-parametric magnetic resonance imaging (mpMRI) [55] . MpMRI has shown utility as a second-line diagnostic tool in lieu of TRUS biopsy [55] . It allows preferential detection of those with intermediateand high-risk PCs more likely to benefit from intervention, thereby avoiding detection of cancers unlikely to be clinically significant [55] . A cost-effectiveness analysis in the Netherlands has demonstrated similar costs for both mpMRI and TRUS pathways, but with a superior HRQoL in the mpMRI cohort due to reduced interventions for lowrisk disease [56] . In addition, mpMRI has been demonstrated to aid correct risk stratification of patients prior to enrolment in an AS protocol [57] .
Limitations
Our study has several limitations. Firstly, probabilities are drawn from a PC screening study performed on a cohort of Swedish men. We did not adjust for Australia's higher incidence of PC as this may merely be an artefact of detection bias [58] .
While we did account for immediate costs of complications for RRP, such as readmission within 30 days for haematoma or infection, we did not account for cost of pads, incontinence surgeries or other long-term treatment complication costs. However, analysis of post-procedure costs in the sensitivity analysis reveals this is highly unlikely to have had significant effect on the model's outcome.
Costs were not adjusted for societal costs of time off work for treatment, and likewise we did not adjust for loss of ability to work from terminal disease. However, it is argued by many health economists that these time costs exaggerate the true cost of a disease on the economy [59] . Our study was not intended to capture a societal perspective; therefore, it may have underestimated the total societal costs associated with screening, treatment or premature death.
A further limitation is utilisation of a time horizon of 20 years instead of a lifelong time horizon. As demonstrated in our sensitivity analysis, a longer time horizon led to increased cost effectiveness in both models, particularly Scenario 1, although its ICER remained well above the WTP threshold, and as such did not change the decision outcome (Table 4) .
Another limitation is the use of non-time-dependant probabilities for disease recurrence post-treatment, and for development of metastases following disease recurrence. However, sensitivity analysis reveals the model to be relatively insensitive to these variables, and consequently it is unlikely this affected model outcomes.
The most significant limitation of our study compared with an actuarial population screening programme is that the cohort of men that entered the model were aged between 50 and 69 years in a uniform distribution to better parallel the recruitment method of the Göteborg study. A programme where all participants first underwent screening at age 50 should allow earlier detection of PCs and potentially increase the LYG. When we ran our model with a uniform entry age of 50 years, the cost effectiveness of both models improved (Table 4) . However, as the diagnostic probabilities were drawn from Göteborg data and not age stratified, these results are unlikely to be representative of the true benefit of commencing screening earlier.
Lastly, it should also be pointed out that the unscreened control cohort in the Göteborg study, whilst not formally invited to screening, were not PSA naïve, and still underwent a significant number of PSA tests and TRUS biopsies as a part of random opportunistic screening. In this regard, the Göteborg study, and consequently our model, represents the benefits of a formal population screening programme compared with a population exposed to opportunistic screening only. In a truly unscreened, PSAnaïve population, it is likely that the mortality differences would be greater still, and the cost per additional QALY considerably more favourable.
Conclusions
Our model is a comprehensive Cost-Utility analysis of a theoretical PSA-based PC screening programme in Australia. In our base-case scenario, PC population-based screening with an invitation to participate every 2 years for men aged 50-69 years was not found to be cost effective when compared with a commonly assumed WTP threshold. It was, however, more cost effective per LYG than the current Australian population screening programme for breast cancer. When the scenario optimised treatment postdiagnosis to focus on AS, rather than primary intervention for low-risk disease, our screening model was cost effective after 20 years of follow-up. PSA-based population screening may be cost effective when compared with opportunistic screening alone if low-risk PC diagnoses can be successfully uncoupled from primary definitive treatment.
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